Ultragenyx shares were down after announcing the Phase III drug candidate UX007 failed to hit the mark as a treatment for patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) who are experiencing disabling paroxysmal movement disorders.

Shares of Ultragenyx Pharmaceuticals were down after the company announced its Phase II drug UX007 to treat seizures failed to meet trial goals.